Motility and invasion capacity of canine mammary tumor cells treated with oseltamivir.

<p>CMA07 and CMT-U27 cell migration was evaluated by time-lapse following treatment with various oseltamivir phosphate concentrations (0.305 μM, 3.05 μM and 30.5 μM) or PBS as control. Representative images (A) and quantification of results (B) after wounding show an altered migration capacity upon treatment. CMT-U27 cells treated with 3.05 μM and 30.5 μM of oseltamivir phosphate for 12, 24 and 40 hours migrated faster than PBS-treated cells. Statistically significant differences were also observed for the lowest concentration tested (0.305 μM) at the longest time point tested (40 hours). Data are presented as means ±SEM from separated experiments. *<i>p</i><0.05 **<i>p</i><0.01; ***<i>p</i><0.001. No significant differences were observed between oseltamivir phosphate-treated and control on CMA07 cells. (C) CMT-U27 invasive capacity <i>in vitro</i> was studied using a Biocoat Matrigel invasion chamber assay for 6 hours of oseltamivir phosphate treatment. Cells treated with 3.05 μM (*<i>p</i><0.05) and 30.5 μM (**<i>p</i><0.01) oseltamivir phosphate showed a significantly increased invasive capacity when compared to PBS-treated cells. For the 0.305 μM oseltamivir phosphate treatment no statistically significant differences were observed (ns <i>p</i>>0.05).